Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.

Gene therapy and gene editing are on the cutting edge of modern biotechnology. Gene therapies are used to correct genetic abnormalities by introducing genetic material at a cellular level and ...

The group had a bad week after turmoil at the FDA, continuing a long period of underperformance following the pandemic.

The universe’s expansion is accelerating, not decelerating. Our understanding of how the universe works may need an update.

The healthcare sector, as measured by Health Care Select Sector SPDR Fund (NYSEARCA:XLV), with 12.12% weightage on the S&P ...

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...

Elo Mutual Pension Insurance trimmed its stake in Vertex Pharmaceuticals by 4% in Q4, now holding $9.49 million in shares. Several other institutional investors also made notable adjustments, with ...

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug ...

The equity portion of the Abrdn Healthcare Investors Fund fell (gross of fees) but outperformed its custom benchmark over the ...

With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...

Stories and news about Mitchell Gold from GeekWire.

AbbVie, Danaher, Thermo Fisher Scientific, Cognizant Technology Solutions, Vertex Pharmaceuticals, Alnylam Pharmaceuticals, ...